FDA shortens monitoring time for first IMDELLTRA doses in small cell lung cancer treatment

The FDA has approved a reduction in the recommended monitoring time for the first two doses of Amgen's IMDELLTRA, a treatment for extensive-stage small cell lung cancer (ES-SCLC), from 22-24 hours to 6-8 hours. This change allows patients to spend less time in healthcare settings during initial treatment, potentially easing the treatment burden and making it more accessible in community oncology practices. Patients will still receive follow-up assessments the day after these doses. This update reflects Amgen's commitment to improving patient care and may enable more patients to receive treatment closer to home.

Following the FDA's approval to shorten monitoring time for Amgen's IMDELLTRA treatment, Amgen's stock shows stability on Pluang. As of Sep 14, 2026 20:12 WIB, AMGN trades at USD 377.43 with a slight 1-day increase of 0.02%. The company maintains a strong market cap of $204.01 billion and a dividend yield of 2.67%.